TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00781131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: pregabalin 75 or 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: pregabalin 75 or 150 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: lactulose placebo
Study: NCT02252484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Loss Program
Description: Program has four main components: diet, physical activity, coaching and diet and exercise monitoring. The program is tailored to each individual in the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care for this patient population.
Study: NCT00117585

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment Phase 1
Description: * Patient Education~* Physical Therapy Exercises~* Increased Salt Intake~* Elevation of head of bed with 2-4 inch wedge~* Medication Review by MD, Pharma

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment Phase 2
Description: Subjects receive Treatment Phase 2 if they are still orthostatic after receiving Treatment Phase 1.~* Fludrocortisone~* Salt tablet

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment Phase 3
Description: Subjects still experiencing orthostatic hypotension after receiving Treatment Phases 1 and 2 move on to Treatment Phase 3. Individualized treatment is based on subspecialty or orthostatic hypotension consultation at the medical center. Subjects are followed for the duration of their hospital stay, on average 4 weeks.
Study: NCT02981602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS-HBVRx
Description: Ascending multiple doses of IONIS-HBVRx by subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03049137

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer Guided Stent Augmentation
Description: Defective alveolar ridge is to be replaced by simultaneous implant placement with ring graft augmentation (Trephine Drill to obtain the ring graft autogenous bone) using computer guided stent and covered with Platelet-rich fibrin (PRF), by using venous blood from the patient, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 Revolution Per Minute (RPM) for 10 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free Hand Augmentation
Description: Defective alveolar ridge is to be replaced by Free Hand simultaneous implant placement with ring graft augmentation (Trephine Drill to obtain the ring graft autogenous bone) and covered with Platelet-rich fibrin (PRF), by using venous blood from the patient, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM for 10 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-rich fibrin (PRF)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: implant
Study: NCT04212325

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group C (Continuous sciatic nerve block)
Description: Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation. After Catheter placement outcome measures will be assessed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group S (sciatic nerve block)
Description: Patients randomized to this group will receive a sciatic nerve block at the popliteal location 1-3 cm cephalad to the sciatic bifurcation. After single injection sciatic nerve block, outcome measures will be assessed.
Study: NCT02291510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Met DR
Description: metformin delayed-release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Met DR
Description: metformin delayed-release tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Met XR
Description: metformin extended-release tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Met IR
Description: metformin immediate-release tablets
Study: NCT03049137

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implant
Study: NCT03455023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmaceutical care
Description: Patients receive pharmaceutical care including individualized evaluation and intervention of adherence, efficacy and safety in cancer pain treatment.
Study: NCT02440100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06648671
Description: experimental Pfizer compound which will be dosed as oral suspension, once a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06648671
Description: experimental Pfizer compound which will be dosed as oral suspension, once a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06648671
Description: experimental Pfizer compound which will be dosed as oral suspension, once a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06648671
Description: experimental Pfizer compound which will be dosed as oral suspension, once a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06648671
Description: experimental Pfizer compound which will be dosed as oral suspension, once a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06648671
Description: experimental Pfizer compound which will be dosed as oral suspension, once a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06648671
Description: experimental Pfizer compound which will be dosed as oral suspension, once a day for 14 days
Study: NCT01601574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Watchers modified program
Description: Weight Watchers: For people with Type 2 diabetes including (1) weekly standard in-person Weight Watchers meetings, (2) use of the standard Weight Watchers online program and tools, and (3) two scheduled telephone consultations with a Certified Diabetes Educator (CDE) who will assist the participant in tailoring the standard Weight Watchers program to accommodate the participant's diabetes-related status, with additional unlimited phone and email access to CDEs at the participant's request

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care group
Description: One session of in-person diabetic nutritional counseling with a registered dietitian, with follow-up written educational materials.
Study: NCT00698568

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes simplex candidate vaccine- adjuvanted GSK 208141
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection, 3 doses
Study: NCT03033303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hu3F8
Description: Day 1: hu3F8 infused iv over \~30 to 90 minutes. Day 3: hu3F8 infused iv over \~30 to 90 minutes. Day 5: hu3F8 infused iv over \~30 to 90 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Days -4 to 0: GM-CSF 250 mcg/m2/day, subcutaneously. Days 1 to 5: GM-CSF 500 mcg/m2/day, subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Isotretinoin is administered at 160 mg/m2/d, divided into two doses, x14 days.
Study: NCT03385018

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by laparoscopic approach
Description: * Total gastrectomy with D2(D2-10) lymph node dissection by laparoscopic approach~* The number of trocars is 6 or less~* Roux-en-Y esophagojejunostomy with any stapling method~* Enough(negative) margin from tumor~* LN station #1, 2, 3, 4d, 4sb, 5, 6, 7, 8a, 9, (10), 11p, 11d, 12a should be examined~* Washing cytology~* Frozen biopsy for surgical margin at surgeons discretion~* Complete omentectomy for grossly serosa-involved tumor~* Combined organ resection only in cholecystectomy and splenectomy~* Indwelling nasogastric tube and drainage catheter at surgeons discretion~* D2 lymphadenectomy should be performed : dissection of LN stations No.4d, 4sb, 4sa, 2, 10 (splenic hilar LN can be left according to the clinical stage), 6, 5, 12a, 8a, 9, 7, 1, 3, 11p, 11d with prevention of pancreatic injury during suprapancreatic dissection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by open conventional approach
Description: * Total gastrectomy with D2(D2-10) lymph node dissection by open conventional approach~* Roux-en-Y esophagojejunostomy with any stapling method~* Enough(negative) margin from tumor~* LN station #1, 2, 3, 4d, 4sb, 5, 6, 7, 8a, 9, (10), 11p, 11d, 12a should be examined~* Washing cytology~* Frozen biopsy for surgical margin at surgeons discretion~* Complete omentectomy for grossly serosa-involved tumor~* Indwelling nasogastric tube and drainage catheter at surgeons discretion~* D2 lymphadenectomy should be performed : dissection of LN stations No.4d, 4sb, 4sa, 2, 10 (splenic hilar LN can be left according to the clinical stage), 6, 5, 12a, 8a, 9, 7, 1, 3, 11p, 11d with prevention of pancreatic injury during suprapancreatic dissection
Study: NCT04950699

Intervention type: GENETIC
Intervention: Single-nucleotide Polymorphism of genes related with Dyslipidemia
Description: This study is an observational study to study the effect of different genotypes on the incidence of myocardial infarction

Intervention type: GENETIC
Intervention: Single-nucleotide Polymorphism of genes related with Dyslipidemia
Description: This study is an observational study to study the effect of different genotypes on the incidence of myocardial infarction
Study: NCT01314651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulus Control and Sleep Restriction
Description: 5 instructions in stimulus control and individually-tailored sleep restriction

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Lifestyle Modification
Description: 5 instructions in changing general lifestyle habits (maintaining consistent liquid intake, range of motion exercises, eating a serving of protein in the morning, etc.)
Study: NCT02843568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard fractionation
Description: 60-66y Gy delivered in 1.8-2.0 Gy fractions over 30-36 treatments

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard fractionation
Description: 60-66y Gy delivered in 1.8-2.0 Gy fractions over 30-36 treatments

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: 40-60 Gy delivered in 5-20 Gy fractions over 3-8 treatments

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: 40-60 Gy delivered in 5-20 Gy fractions over 3-8 treatments

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Four Dimensional Computed Tomographic Imaging (4DCT)
Description: Subjects undergo a total of 7 research-ordered four dimensional computed tomographic imaging (4DCT) scans: 1 at simulation, and 2 scans at each of the 3 post-radiation therapy time points (3, 6, and 12 months). 4DCT determines lung tissue elasticity and for standard of care radiation treatment planning.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four Dimensional Computed Tomographic Imaging (4DCT)
Description: Subjects undergo a total of 7 research-ordered four dimensional computed tomographic imaging (4DCT) scans: 1 at simulation, and 2 scans at each of the 3 post-radiation therapy time points (3, 6, and 12 months). 4DCT determines lung tissue elasticity and for standard of care radiation treatment planning.
Study: NCT02313142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leg exercises
Study: NCT03879798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-3201b
Description: 100 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Irinotecan 125 mg/m\^2 intravenously on days 1 and 8 every 3 weeks in a 21-day cycle.
Study: NCT05054335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Assessment
Description: Undergo walking function assessment with optical motion capture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo bi-plane dynamic X-ray imaging
Study: NCT04139317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: INC280 tablets were administered orally at 400 mg on a continuous twice daily (BID) dosing schedule, from Day 1 until Day 21 of each 21-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab was administered by intravenous infusion at 200 mg once every 3 weeks (Q3W).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab was administered by intravenous infusion at 200 mg once every 3 weeks (Q3W).
Study: NCT01023100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP 690,550 oral solutions
Description: flavored and unflavored prototype CP-690,550 formulations
Study: NCT02440100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06648671
Description: experimental Pfizer compound which will be dosed as oral suspension, once a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06648671
Description: experimental Pfizer compound which will be dosed as oral suspension, once a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: commercial available oral solution of 2 mg midazolam as CYP3A probe substrate for drug interaction evaluation. Midazolam will be given as single dose with and without co-administration of PF-06648671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo which will be given as oral suspension, once a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo which will be given as oral suspension, once a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo which will be given as oral suspension, once a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo which will be given as oral suspension, once a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo which will be given as oral suspension, once a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo which will be given as oral suspension, once a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo which will be given as oral suspension, once a day for 14 days
Study: NCT03916003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: primaquine
Description: Primaquine regimen over 7 days (1.0 mg/kg/day for 7 days)
Study: NCT04236349

Intervention type: GENETIC
Intervention: immunogenetics
Description: blood samples at day 0, week 2, month 2; at the end of treatment (month 6 or month 9 or month 12 depend on treatment duration)
Study: NCT02512718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: Comparison of FOLE vs. SOLE

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soybean oil lipid emulsion
Description: Comparison of FOLE vs. SOLE
Study: NCT02440100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo which will be given as oral suspension, once a day for 14 days
Study: NCT00039416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02580318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: breathalyzer
Study: NCT03697785

Intervention type: DEVICE
Group type: OTHER
Intervention: Beacon Care System
Description: Beacon has been developed by Mermaid Care in Denmark. BEACON is a critical care ventilation assist system (http://beaconcaresystem.com/beacon-5/), which potentially enables better ventilation strategies and a more efficient patient care workflow. As an add-on to standard ventilation systems it provides ventilation recommendations 24/7 based on non-stop, personalised monitoring/diagnostics of patients. Based on unique mathematical algorithms and physiological models, it recommends changes in ventilation settings, supporting the critical decision-making processes.
Study: NCT02869932

Intervention type: RADIATION
Group type: OTHER
Intervention: Lung CT scan
Description: Lung CT scan without injection
Study: NCT03697785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beacon Care System
Description: Beacon has been developed by Mermaid Care in Denmark. BEACON is a critical care ventilation assist system (http://beaconcaresystem.com/beacon-5/), which potentially enables better ventilation strategies and a more efficient patient care workflow. As an add-on to standard ventilation systems it provides ventilation recommendations 24/7 based on non-stop, personalised monitoring/diagnostics of patients. Based on unique mathematical algorithms and physiological models, it recommends changes in ventilation settings, supporting the critical decision-making processes.
Study: NCT03850392

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy (Thermogel - Artsana or Cryo+ - Cryonic)
Description: cold application (ice 30 min or cold CO2 2 min) twice during 1 day at an 8 hour-interval

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy (Thermogel - Artsana or Cryo+ - Cryonic)
Description: cold application (ice 30 min or cold CO2 2 min) twice during 1 day at an 8 hour-interval
Study: NCT02493361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pIL-12
Study: NCT04579263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal microbiota
Description: Transplantation of fecal microbiota of healthy donor with normal body mass index

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal microbiota
Description: Transplantation of fecal microbiota of healthy donor with normal body mass index
Study: NCT04059926

Intervention type: OTHER
Intervention: insert apossing lumen metal stent
Description: insert apossing lumen metal stent
Study: NCT01260233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking cessation program
Description: Smoking cessation program includes:~* brief smoking cessation counselling by preadmission nurse (less than 5 minutes)~* smoking cessation brochures~* referral to the Smokers' Helpline telephone advice line, run by the Canadian Cancer Society~* free transdermal nicotine replacement therapy for 6 weeks Smokers of 10 cigarettes per day or more receive 4 weeks of nicoderm 21mg/day, 1 week of 14mg/day and 1 week of 7mg/day Smokers of less than 10 cigarettes per day receive 4 weeks of nicoderm 14mg/day and 2 weeks of 7mg/day
Study: NCT01490346

Intervention type: DRUG
Intervention: Initiation of anti-retroviral therapy
Description: Subjects begin taking a preferred initial anti-retroviral regimens as determined by their primary care provider. Intracellular levels of those medications are measured.
Study: NCT03749551

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac magnetic resonance (CMR) post haemodialysis
Description: patients will undergo a second CMR scan immediately after receiving haemodialysis (native CMR study)
Study: NCT00267007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PROCRIT 40,000 IU QW
Description: Epoetin alpha (PROCRIT) 40,000 IU every week (QW) for 18 weeks (IV or SC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent volume to PROCRIT (1 mL) administered (QW) for 18 weeks (IV or SC)
Study: NCT03373266

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: anesthesia was maintained with Sevoflurane 1-2%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: anesthesia was maintained with isoflurane 1-2%.
Study: NCT01614925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emdogain
Description: Periodontal surgery with the additional use of Straumann® Emdogain

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal surgery
Description: Periodontal surgery alone
Study: NCT04267016

Intervention type: DIAGNOSTIC_TEST
Intervention: TruGraf Testing - Peripheral blood gene expression profiling
Description: 5 mL collection PAXgene blood sample
Study: NCT03970668

Intervention type: DRUG
Intervention: Linagliptin 5 mg Oral Tablet
Description: Patients received linagliptin 5mg once daily orally plus a basal bolus insulin scheme, if they presented hyperglycemia (glucose levels above than 140 mg/dl)

Intervention type: DRUG
Intervention: Insulin
Description: Patients received a basal bolus insulin scheme, if they presented hyperglycemia (glucose levels above than 140 mg/dl)
Study: NCT02438865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate instillation of intravesical chemotherapy-Epirubicin-

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintainance therapy of intravesical chemotherapy-Epirubicin-
Study: NCT01147016

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2Bi-armed activated T cells
Description: Total of 4 of the T cell infusions intravenously over a period of 1 month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: As prescribed by physician, standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: As prescribed by physician, standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: As prescribed by physician, standard of care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Immune studies will be done pre-immunotherapy, prior to the third infusion of activated T-cells, at the time of surgery, and 1 month after immunotherapy. If there are positive findings, additional optional studies will be done at 3, 6, and 12 months, if the immune studies show changes worthy of follow-up studies.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: As prescribed by physician, standard of care.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: As recommended by physician, post immunotherapy.